SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Barbara Jordan Synthetic CCD

PatientBarbara Jordan
Date of birth1982-02-21
IdentifiersMRN HR-ML030-SYN; SSN (made up) 000-30-6852
Document date2026-11-01
AuthorEvangeline Moss, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy. Concerns: She wants to keep teaching and speaking without her health becoming the subject; She wants to know whether any treatment can slow the disease; She wants to stay safe on her feet and to have energy left at the end of a teaching day. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule dailyOne capsule dailyOral route2026-03-02activeS
Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once toleratedOne tablet three times a dayOral route2026-03-16 to 2026-04-20completedS
Baclofen 10 mg oral tablet, one tablet three times a dayOne tablet three times a dayOral route2026-04-20activeS
Mirabegron 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center300 mg on day 1 and day 15 (given), then 600 mg every 6 monthsIntravenous route2026-05-04activeS

Procedures

ProcedureDatesStatusEvidence
Bladder scan for post-void residual volume2026-03-02 to 2026-03-02completedS
MRI of the brain with and without gadolinium (3D T2-FLAIR, T2, and T1 before and after contrast)2026-03-16 to 2026-03-16completedS
MRI of the cervical and thoracic spine with and without gadolinium2026-03-16 to 2026-03-16completedS
Ocrelizumab 300 mg intravenous infusion (first half-dose) after premedication, with observation for at least one hour afterwards2026-05-04 to 2026-05-04completedS
Ocrelizumab 300 mg intravenous infusion (second half-dose) after premedication, with observation for at least one hour afterwards2026-05-18 to 2026-05-18completedS
MRI of the brain without gadolinium (re-baseline on therapy)2026-10-26 to 2026-10-26completedS
Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip2026-08-17 to 2026-08-17completedS
Advance care planning conversation, about 20 minutes2026-08-17 to 2026-08-17completedS
Screening mammogram, both breasts2026-08-31 to 2026-08-31completedS

Immunizations

DateVaccineStatusEvidence
2026-03-16Pneumococcal conjugate vaccine PCV20completedS
2026-03-16Recombinant zoster vaccine, dose 1 of 2completedS
2026-03-16Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS
2026-03-16Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-04-20Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-04-20Recombinant zoster vaccine, dose 2 of 2completedS
2026-10-26Influenza vaccine, inactivated, this seasoncompletedS
2026-10-26COVID-19 vaccine, mRNA, this seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1978Walking difficulty needing a cane in her last years in the House, attributed publicly at the time to a knee problemD (CLM-0005)
1979Multiple sclerosis diagnosed around the time she left Congress, as later revealed; records of that evaluation are not available to this clinicD (CLM-0006)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
She wants to keep teaching and speaking without her health becoming the subjectactiveS
She wants to know whether any treatment can slow the diseaseactiveS
She wants to stay safe on her feet and to have energy left at the end of a teaching dayactiveS

Assessment

Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-10-26; Lymphocytes [#/volume] in Blood by Automated count 1.5 on 2026-10-26; Hemoglobin [Mass/volume] in Blood 13.5 on 2026-10-26; Platelets [#/volume] in Blood by Automated count 255 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 93 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2026-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-10-26; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 72 on 2026-03-02; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-03-02; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-03-02; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 520 on 2026-03-02; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-06-29; IgG [Mass/volume] in Serum or Plasma 1010 on 2026-10-26; IgM [Mass/volume] in Serum or Plasma 72 on 2026-10-26; IgA [Mass/volume] in Serum or Plasma 210 on 2026-03-02; JC virus Ab Index in Serum or Plasma by Immunoassay 0.14 on 2026-03-02; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-06-29; CD19 cells [#/volume] in Blood 3 on 2026-06-29; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-08-17; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-08-17; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 110 on 2026-08-17; Cholesterol in HDL [Mass/volume] in Serum or Plasma 56 on 2026-08-17; Triglyceride [Mass/volume] in Serum or Plasma 98 on 2026-08-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-08-17 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spineresolvedconfirmed G35.DS — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.
Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosisactiveconfirmed G35.B1S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.
Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of fallsactiveconfirmed R26.89S — Synthetic modern coding anchored to her documented cane.
Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residualactiveconfirmed N31.9S — Synthetic; common in multiple sclerosis. No public source describes her bladder.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic laboratory finding at intake.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-02Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2026-03-02Lymphocytes [#/volume] in Blood by Automated count1.910*3/uL1-4.8 10*3/uLNormalS
2026-03-02Hemoglobin [Mass/volume] in Blood13.2g/dL12-15.5 g/dLNormalS
2026-03-02Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
2026-03-02Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
2026-03-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M96mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-02Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-03-02Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L10-35 U/LNormalS
2026-03-02Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma72U/L35-105 U/LNormalS
2026-03-02Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.2-1.2 mg/dLNormalS
2026-03-02Thyrotropin [Units/volume] in Serum or Plasma1.8m[IU]/L0.4-4.5 mIU/LNormalS
2026-03-02Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma520pg/mL232-1245 pg/mLNormalS
2026-03-0225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma17ng/mL30-100 ng/mLLowS
2026-03-02IgG [Mass/volume] in Serum or Plasma1080mg/dL700-1600 mg/dLNormalS
2026-03-02IgM [Mass/volume] in Serum or Plasma110mg/dL40-230 mg/dLNormalS
2026-03-02IgA [Mass/volume] in Serum or Plasma210mg/dL70-400 mg/dLNormalS
2026-03-02JC virus Ab Index in Serum or Plasma by Immunoassay0.14{index}Below 0.20 negative; 0.20 to 0.40 indeterminate; above 0.40 positiveNormalS
2026-03-02Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-06-29Leukocytes [#/volume] in Blood by Automated count5.910*3/uL4-11 10*3/uLNormalS
2026-06-29Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
2026-06-29Hemoglobin [Mass/volume] in Blood13.4g/dL12-15.5 g/dLNormalS
2026-06-29Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-06-29CD19 cells [#/volume] in Blood3/uLExpected to be depleted after an anti-CD20 therapyLowS
2026-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
2026-06-2925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2026-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-08-17Hemoglobin A1c/Hemoglobin.total in Blood5.4%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
2026-08-17Cholesterol [Mass/volume] in Serum or Plasma186mg/dL<=199 mg/dLNormalS
2026-08-17Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation110mg/dL<=129 mg/dLNormalS
2026-08-17Cholesterol in HDL [Mass/volume] in Serum or Plasma56mg/dL>=50 mg/dLNormalS
2026-08-17Triglyceride [Mass/volume] in Serum or Plasma98mg/dL<=149 mg/dLNormalS
2026-10-26Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-10-26Lymphocytes [#/volume] in Blood by Automated count1.510*3/uL1-4.8 10*3/uLNormalS
2026-10-26Hemoglobin [Mass/volume] in Blood13.5g/dL12-15.5 g/dLNormalS
2026-10-26Platelets [#/volume] in Blood by Automated count25510*3/uL150-400 10*3/uLNormalS
2026-10-26IgG [Mass/volume] in Serum or Plasma1010mg/dL700-1600 mg/dLNormalS
2026-10-26IgM [Mass/volume] in Serum or Plasma72mg/dL40-230 mg/dLNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M93mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L10-35 U/LNormalS
2026-08-17Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-02Body height173cmS
2026-03-02Body weight84kgS
2026-03-02Body mass index (BMI) [Ratio]28.1kg/m2S
2026-03-02Systolic blood pressure124mm[Hg]S
2026-03-02Diastolic blood pressure78mm[Hg]S
2026-03-02Heart rate76/minS
2026-03-02Respiratory rate16/minS
2026-03-02Body temperature36.7CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-03-16Body height173cmS
2026-03-16Body weight84.2kgS
2026-03-16Body mass index (BMI) [Ratio]28.1kg/m2S
2026-03-16Systolic blood pressure122mm[Hg]S
2026-03-16Diastolic blood pressure76mm[Hg]S
2026-03-16Heart rate74/minS
2026-03-16Respiratory rate16/minS
2026-03-16Body temperature36.6CelS
2026-03-16Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-20Body height173cmS
2026-04-20Body weight83.8kgS
2026-04-20Body mass index (BMI) [Ratio]28kg/m2S
2026-04-20Systolic blood pressure120mm[Hg]S
2026-04-20Diastolic blood pressure76mm[Hg]S
2026-04-20Heart rate72/minS
2026-04-20Respiratory rate16/minS
2026-04-20Body temperature36.6CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-29Body height173cmS
2026-06-29Body weight83.5kgS
2026-06-29Body mass index (BMI) [Ratio]27.9kg/m2S
2026-06-29Systolic blood pressure118mm[Hg]S
2026-06-29Diastolic blood pressure74mm[Hg]S
2026-06-29Heart rate74/minS
2026-06-29Respiratory rate16/minS
2026-06-29Body temperature36.8CelS
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-26Body height173cmS
2026-10-26Body weight83.2kgS
2026-10-26Body mass index (BMI) [Ratio]27.8kg/m2S
2026-10-26Systolic blood pressure120mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate72/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-17Body height173cmS
2026-08-17Body weight83.4kgS
2026-08-17Body mass index (BMI) [Ratio]27.9kg/m2S
2026-08-17Systolic blood pressure118mm[Hg]S
2026-08-17Diastolic blood pressure74mm[Hg]S
2026-08-17Heart rate74/minS
2026-08-17Respiratory rate16/minS
2026-08-17Body temperature36.7CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-03-02Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapyfinishedS
2026-03-16Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapyfinishedS
2026-04-20Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusionfinishedS
2026-06-29Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and moodfinishedS
2026-10-26Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and workfinishedS
2026-08-17Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 2017 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluationcompletedGL-MCDONALD-2017, GL-MAGNIMS-2021S
Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-upcompletedGL-AAN-DMT-2018, GL-MCDONALD-2017, GL-MAGNIMS-2021S
Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dosecompletedGL-AAN-DMT-2018, GL-AAN-VAX-2019, GL-CDC-IMZ-2026S
Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bagcompletedGL-AAN-DMT-2018, GL-NICE-MS-2022S
Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretchingcompletedGL-NICE-MS-2022, GL-CMID-2026S
Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worseningcompletedGL-NICE-MS-2022S
Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool watercompletedGL-NICE-MS-2022S
Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclosecompletedGL-JAN-MS, GL-ADAS
Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid coursescompletedGL-CMID-2026, GL-NICE-MS-2022S
Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any timecompletedGL-USPSTF-DEP-2023, GL-NICE-MS-2022, GL-CMID-2026S
On the consultant's advice: ocrelizumab 300 mg on day 1 and day 15 and then 600 mg every 6 months, after the vaccines and at least two weeks after the last inactivated dose, with premedication and observation; blood count and immunoglobulins before each dose; a re-baseline brain MRI three to six months after the first dose and then yearly; baclofen titrated to 10 mg three times a day; mirabegron with a blood pressure check at each visitcompletedGL-AAN-DMT-2018, GL-OCR-LABEL, GL-MAGNIMS-2021, GL-NICE-MS-2022S

Goals

GoalTargetStatusOutcomeProvenance
Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks2026-06-29completedPrimary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeksS
No falls through eight months2026-10-26completedNo falls; one near-fall in the summer heatS
25-hydroxyvitamin D at least 30 ng/mL within four months2026-06-29completed34 ng/mL at four monthsS
Up no more than once a night to pass urine within three months2026-06-29completedOnce a night or less on mirabegronS
Keep her full teaching and speaking schedule with the accommodations she chooses2026-10-26completedFull schedule kept; accessible rooms, seating and parking in placeS
No new or enlarging T2 lesions on the re-baseline MRI2026-10-26completedNo new or enlarging T2 lesionsS

Functional Status

Mental Status